Koen Vandenbroeck

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5730321/publications.pdf

Version: 2024-02-01

118 papers	3,590 citations	117453 34 h-index	182168 51 g-index
119 all docs	119 docs citations	119 times ranked	5304 citing authors

#	Article	IF	Citations
1	Identification of the genetic mechanism that associates L3MBTL3 to multiple sclerosis. Human Molecular Genetics, 2022, 31, 2155-2163.	1.4	4
2	Boosting Cholesterol Efflux from Foam Cells by Sequential Administration of rHDL to Deliver MicroRNA and to Remove Cholesterol in a Tripleâ€Cell 2D Atherosclerosis Model. Small, 2022, 18, e2105915.	5.2	13
3	Pathophysiology of Atherosclerosis. International Journal of Molecular Sciences, 2022, 23, 3346.	1.8	208
4	Novel Transcript Discovery Expands the Repertoire of Pathologically-Associated, Long Non-Coding RNAs in Vascular Smooth Muscle Cells. International Journal of Molecular Sciences, 2021, 22, 1484.	1.8	5
5	Genomic Multiple Sclerosis Risk Variants Modulate the Expression of the ANKRD55â€“IL6ST Gene Region in Immature Dendritic Cells. Frontiers in Immunology, 2021, 12, 816930.	2.2	6
6	Cholesterol Efflux Efficiency of Reconstituted HDL Is Affected by Nanoparticle Lipid Composition. Biomedicines, 2020, 8, 373.	1.4	11
7	BIRC6 Is Associated with Vulnerability of Carotid Atherosclerotic Plaque. International Journal of Molecular Sciences, 2020, 21, 9387.	1.8	5
8	A New Risk Variant for Multiple Sclerosis at 11q23.3 Locus Is Associated with Expansion of CXCR5+ Circulating Regulatory T Cells. Journal of Clinical Medicine, 2020, 9, 625.	1.0	5
9	The Rare IL22RA2 Signal Peptide Coding Variant rs28385692 Decreases Secretion of IL-22BP Isoform-1, -2 and -3 and Is Associated with Risk for Multiple Sclerosis. Cells, 2020, 9, 175.	1.8	1
10	NLRP3 inflammasome as prognostic factor and therapeutic target in primary progressive multiple sclerosis patients. Brain, 2020, 143, 1414-1430.	3.7	92
11	Interactome of the Autoimmune Risk Protein ANKRD55. Frontiers in Immunology, 2019, 10, 2067.	2.2	13
12	Pharmacological Targeting of the ER-Resident Chaperones GRP94 or Cyclophilin B Induces Secretion of IL-22 Binding Protein Isoform-1 (IL-22BPi1). International Journal of Molecular Sciences, 2019, 20, 2440.	1.8	2
13	Exome sequencing in multiple sclerosis families identifies 12 candidate genes and nominates biological pathways for the genesis of disease. PLoS Genetics, 2019, 15, e1008180.	1.5	46
14	Inflammation in human carotid atheroma plaques. Cytokine and Growth Factor Reviews, 2018, 39, 62-70.	3.2	18
15	The era of GWAS is over â€“ Yes. Multiple Sclerosis Journal, 2018, 24, 256-257.	1.4	3
16	Long Interleukin-22 Binding Protein Isoform-1 Is an Intracellular Activator of the Unfolded Protein Response. Frontiers in Immunology, 2018, 9, 2934.	2.2	11
17	Characterization of Carotid Smooth Muscle Cells during Phenotypic Transition. Cells, 2018, 7, 23.	1.8	21
18	Response to interferon-beta treatment in multiple sclerosis patients: a genome-wide association study. Pharmacogenomics Journal, 2017, 17, 312-318.	0.9	28

#	Article	IF	Citations
19	RNAseq based transcriptomics study of SMCs from carotid atherosclerotic plaque: BMP2 and IDs proteins are crucial regulators of plaque stability. Scientific Reports, 2017, 7, 3470.	1.6	21
20	Analysis of Plasminogen Genetic Variants in Multiple Sclerosis Patients. G3: Genes, Genomes, Genetics, 2016, 6, 2073-2079.	0.8	13
21	Novel Insights into the Multiple Sclerosis Risk Gene ANKRD55. Journal of Immunology, 2016, 196, 4553-4565.	0.4	21
22	A role for autophagy in carotid atherosclerosis. European Stroke Journal, 2016, 1, 255-263.	2.7	10
23	Pharmacogenomic study in patients with multiple sclerosis. Neurology: Neuroimmunology and NeuroInflammation, 2015, 2, e154.	3.1	19
24	Cell-specific effects in different immune subsets associated with SOCS1 genotypes in multiple sclerosis. Multiple Sclerosis Journal, 2015, 21, 1498-1512.	1.4	8
25	A functional variant that affects exon-skipping and protein expression ofSP140as genetic mechanism predisposing to multiple sclerosis. Human Molecular Genetics, 2015, 24, 5619-5627.	1.4	43
26	Genome-wide significant association with seven novel multiple sclerosis risk loci. Journal of Medical Genetics, 2015, 52, 848-855.	1.5	34
27	SNPs in the SOCS1 area are strongly associated with multiple sclerosis and may affect regulatory T cells and dendritic cells. Journal of Neuroimmunology, 2014, 275, 51.	1.1	0
28	New insights about ANKRD55 in the experimental autoimmune encephalomyelitis model of Multiple sclerosis. Journal of Neuroimmunology, 2014, 275, 148.	1.1	1
29	Human Endogenous Retrovirus HERV-Fc1 Association with Multiple Sclerosis Susceptibility: A Meta-Analysis. PLoS ONE, 2014, 9, e90182.	1.1	29
30	Autophagic Marker MAP1LC3B Expression Levels Are Associated with Carotid Atherosclerosis Symptomatology. PLoS ONE, 2014, 9, e115176.	1.1	39
31	TNFRSF1A polymorphisms rs1800693 and rs4149584 in patients with multiple sclerosis. Neurology, 2013, 80, 2010-2016.	1.5	28
32	MANBA, CXCR5, SOX8, RPS6KB1 and ZBTB46 are genetic risk loci for multiple sclerosis. Brain, 2013, 136, 1778-1782.	3.7	60
33	Identification of a functional variant in theKIF5A-CYP27B1-METTL1-FAM119Blocus associated with multiple sclerosis. Journal of Medical Genetics, 2013, 50, 25-33.	1.5	59
34	Genome-wide significant association ofANKRD55rs6859219 and multiple sclerosis risk. Journal of Medical Genetics, 2013, 50, 140-143.	1.5	34
35	Oxidative Stress and Proinflammatory Cytokines Contribute to Demyelination and Axonal Damage in a Cerebellar Culture Model of Neuroinflammation. PLoS ONE, 2013, 8, e54722.	1.1	195
36	Fine Mapping and Functional Analysis of the Multiple Sclerosis Risk Gene CD6. PLoS ONE, 2013, 8, e62376.	1.1	23

#	Article	IF	Citations
37	A Trifluoromethyl Analogue of Celecoxib Exerts Beneficial Effects in Neuroinflammation. PLoS ONE, 2013, 8, e83119.	1.1	14
38	Replication study of 10 genes showing evidence for association with multiple sclerosis: validation of TMEM39A, IL12B and CLBL genes. Multiple Sclerosis Journal, 2012, 18, 959-965.	1.4	28
39	Allelic combinations of immune-response genes as possible composite markers of IFN-Î² efficacy in multiple sclerosis patients. Pharmacogenomics, 2012, 13, 1689-1700.	0.6	16
40	Cytokine Gene Polymorphisms and Human Autoimmune Disease in the Era of Genome-Wide Association Studies. Journal of Interferon and Cytokine Research, 2012, 32, 139-151.	0.5	64
41	Chitinase 3-like 1 plasma levels are increased in patients with progressive forms of multiple sclerosis. Multiple Sclerosis Journal, 2012, 18, 983-990.	1.4	54
42	Closing the case ofAPOEin multiple sclerosis: no association with disease risk in over 29â€…000 subjects: Figure 1. Journal of Medical Genetics, 2012, 49, 558-562.	1.5	31
43	ANKRD55 and DHCR7 are novel multiple sclerosis risk loci. Genes and Immunity, 2012, 13, 253-257.	2.2	44
44	A cytokine gene screen uncovers SOCS1 as genetic risk factor for multiple sclerosis. Genes and Immunity, 2012, 13, 21-28.	2.2	56
45	A 4-trifluoromethyl analogue of celecoxib inhibits arthritis by suppressing innate immune cell activation.. Arthritis Research and Therapy, 2012, 14, R9.	1.6	19
46	Allelic combinations of immune-response genes associated with glatiramer acetate treatment response in Russian multiple sclerosis patients. Pharmacogenomics, 2012, 13, 43-53.	0.6	25
47	Analysis of the IL28RA locus as genetic risk factor for multiple sclerosis. Journal of Neuroimmunology, 2012, 245, 98-101.	1.1	9
48	The endoplasmic reticulum protein folding factory and its chaperones: new targets for drug discovery?. British Journal of Pharmacology, 2011, 162, 328-345.	2.7	76
49	Validation of IRF5 as multiple sclerosis risk gene: putative role in interferon beta therapy and human herpes virus-6 infection. Genes and Immunity, 2011, 12, 40-45.	2.2	36
50	Replication of top markers of a genome-wide association study in multiple sclerosis in Spain. Genes and Immunity, 2011, 12, 110-115.	2.2	36
51	IL28B polymorphisms are not associated with the response to interferon-beta in multiple sclerosis. Journal of Neuroimmunology, 2011, 239, 101-104.	1.1	18
52	Pharmacogenomics and Multiple Sclerosis: Moving Toward Individualized Medicine. Current Neurology and Neuroscience Reports, 2011, 11, 484-491.	2.0	43
53	Inhibiting cytokines of the interleukin-12 family: recent advances and novel challenges. Journal of Pharmacy and Pharmacology, 2010, 56, 145-160.	1.2	42
54	The metallopeptide antibiotic bacitracin inhibits interleukin-12 Î±Î²2 and Î²2 secretion. Journal of Pharmacy and Pharmacology, 2010, 57, 213-218.	1.2	8

#	Article	IF	Citations
55	Validation of the CD6 and TNFRSF1A loci as risk factors for multiple sclerosis in Spain. Journal of Neuroimmunology, 2010, 223, 100-103.	1.1	29
56	High affinity binding of hydrophobic and autoantigenic regions of proinsulin to the 70 kDa chaperone DnaK. BMC Biochemistry, 2010, 11, 44.	4.4	6
57	The autoimmune disease-associated KIF5A, CD226 and SH2B3 gene variants confer susceptibility for multiple sclerosis. Genes and Immunity, 2010, 11, 439-445.	2.2	79
58	Single-Nucleotide Polymorphisms in Response to Interferon-Beta Therapy in Multiple Sclerosis. Journal of Interferon and Cytokine Research, 2010, 30, 727-732.	0.5	13
59	IFN-Î² pharmacogenomics in multiple sclerosis. Pharmacogenomics, 2010, 11, 1137-1148.	0.6	20
60	Inhibition of Secretion of Interleukin (IL)-12/IL-23 Family Cytokines by 4-Trifluoromethyl-celecoxib Is Coupled to Degradation via the Endoplasmic Reticulum Stress Protein HERP. Journal of Biological Chemistry, 2010, 285, 6960-6969.	1.6	18
61	Genetic polymorphisms, their allele combinations and IFN-Î² treatment response in Irish multiple sclerosis patients. Pharmacogenomics, 2009, 10, 1177-1186.	0.6	48
62	United Europeans for development of pharmacogenomics in multiple sclerosis network. Pharmacogenomics, 2009, 10, 885-894.	0.6	11
63	IL7RA polymorphisms and chronic inflammatory arthropathies. Tissue Antigens, 2009, 74, 429-431.	1.0	38
64	Pharmacogenomic studies of the anticancer and immunosuppressive thiopurines mercaptopurine and azathioprine. British Journal of Clinical Pharmacology, 2008, 66, 517-528.	1.1	88
65	Refining genetic associations in multiple sclerosis. Lancet Neurology, The, 2008, 7, 567-569.	4.9	90
66	Pharmacogenomics of the response to IFN-Î² in multiple sclerosis: ramifications from the first genome-wide screen. Pharmacogenomics, 2008, 9, 639-645.	0.6	13
67	Signalling, inflammation and arthritis: Crossed signals: the role of interleukin (IL)-12, -17, -23 and -27 in autoimmunity. Rheumatology, 2008, 47, 771-776.	0.9	46
68	IL7RAPolymorphisms and Susceptibility to Multiple Sclerosis. New England Journal of Medicine, 2008, 358, 753-754.	13.9	32
69	Interferon Gamma Allelic Variants. Archives of Neurology, 2008, 65, 349-57.	4.9	33
70	Pharmacogenomics of Type I interferon therapy: A survey of response-modifying genes. Cytokine and Growth Factor Reviews, 2007, 18, 211-222.	3.2	25
71	Study of polymorphisms in the interleukin-4 and IL-4 receptor genes in a population of Brazilian patients with multiple sclerosis. Arquivos De Neuro-Psiquiatria, 2007, 65, 15-19.	0.3	8
72	The MHC2TA ?168A/G and +1614G/C polymorphisms and risk for multiple sclerosis or chronic inflammatory arthropathies. Tissue Antigens, 2007, 70, 247-251.	1.0	10

#	Article	IF	Citations
73	The neuropeptide genes TAC1, TAC3, TAC4, VIP and PACAP(ADCYAP1), and susceptibility to multiple sclerosis. Journal of Neuroimmunology, 2007, 183, 208-213.	1.1	12
74	CTLA4 gene polymorphisms and multiple sclerosis in Northern Ireland. Journal of Neuroimmunology, 2007, 187, 187-191.	1.1	25
75	ITGA4 polymorphisms and susceptibility to multiple sclerosis. Journal of Neuroimmunology, 2007, 189, 151-157.	1.1	15
76	Corrigendum to â€œLinkage disequilibrium screening for multiple sclerosis implicates JAG1 and POU2AF1 as susceptibility genes in Europeansâ€•[J. Neuroimmunol. 179 (2006) 108â€“116]. Journal of Neuroimmunology, 2007, 189, 175-176.	1.1	1
77	Multi-chaperone complexes regulate the folding of interferon-Î³ in the endoplasmic reticulum. Cytokine, 2006, 33, 264-273.	1.4	25
78	The CTLA4 +Â49A/G and CT60 polymorphisms and chronic inflammatory arthropathies in Northern Ireland. Experimental and Molecular Pathology, 2006, 80, 141-146.	0.9	35
79	Polymorphisms in the interleukin-4 and IL-4 receptor genes modify risk for chronic inflammatory arthropathies in women. Experimental and Molecular Pathology, 2006, 81, 239-244.	0.9	9
80	Linkage disequilibrium screening for multiple sclerosis implicates JAG1 and POU2AF1 as susceptibility genes in Europeans. Journal of Neuroimmunology, 2006, 179, 108-116.	1.1	29
81	Celecoxib Inhibits Interleukin-12 Î±Î² and Î²2 Folding and Secretion by a Novel COX2-Independent Mechanism Involving Chaperones of the Endoplasmic Reticulum. Molecular Pharmacology, 2006, 69, 1579-1587.	1.0	40
82	The IFNGâ€“IL26â€“IL22 Cytokine Gene Cluster. , 2006, , 157-174.		2
83	Pharmacogenomics of responsiveness to interferon IFN-Î² treatment in multiple sclerosis: A genetic screen of 100 type I interferon-inducible genes. Clinical Pharmacology and Therapeutics, 2005, 78, 635-635.	2.3	71
84	IFNG polymorphisms are associated with gender differences in susceptibility to multiple sclerosis. Genes and Immunity, 2005, 6, 153-161.	2.2	57
85	Haplotype analysis of the preprotachykinin-1 (TAC1) gene in multiple sclerosis. Genes and Immunity, 2005, 6, 265-270.	2.2	14
86	Polymorphisms in the interleukin-4 and IL-4 receptor genes and multiple sclerosis: a study in Spanish-Basque, Northern Irish and Belgian populations. International Journal of Immunogenetics, 2005, 32, 383-388.	0.8	29
87	The CTLA4 +49 A/G*Gâ€“CT60*G haplotype is associated with susceptibility to multiple sclerosis in Flanders. Journal of Neuroimmunology, 2005, 164, 148-153.	1.1	42
88	Cross-linking approach to affinity capture of protein complexes from chaotrope-solubilized cell lysates. Analytical Biochemistry, 2004, 324, 137-142.	1.1	18
89	New candidate loci for multiple sclerosis susceptibility revealed by a whole genome association screen in a Belgian population. Journal of Neuroimmunology, 2003, 143, 65-69.	1.1	36
90	A genome wide scan for association with multiple sclerosis in a N. Irish case control population. Journal of Neuroimmunology, 2003, 143, 93-96.	1.1	22

#	Article	IF	Citations
91	Polymorphisms in the interferon-Î³/interleukin-26 gene region contribute to sex bias in susceptibility to rheumatoid arthritis. Arthritis and Rheumatism, 2003, 48, 2773-2778.	6.7	43
92	Cytokine gene polymorphisms in multifactorial diseases: gateways to novel targets for immunotherapy?. Trends in Pharmacological Sciences, 2003, 24, 284-289.	4.0	65
93	The Conserved Helix C Region in the Superfamily of Interferon-Î³/Interleukin-10-related Cytokines Corresponds to a High-affinity Binding Site for the HSP70 Chaperone DnaK. Journal of Biological Chemistry, 2002, 277, 25668-25676.	1.6	19
94	Irreversible inhibition of the bacterial cysteine protease-transpeptidase sortase (SrtA) by substrate-derived affinity labels. Biochemical Journal, 2002, 366, 953-958.	1.7	75
95	PRIMITIVE ENDOTHELIAL CELL LINES FROM THE PORCINE EMBRYONIC YOLK SAC. In Vitro Cellular and Developmental Biology - Animal, 2002, 38, 334.	0.7	14
96	Chromosome 7q21â€“22 and multiple sclerosis: evidence for a genetic susceptibility effect in vicinity to the protachykinin-1 gene. Journal of Neuroimmunology, 2002, 125, 141-148.	1.1	23
97	Interleukin-12 p40 polymorphism and susceptibility to multiple sclerosis. Annals of Neurology, 2002, 52, 524-525.	2.8	16
98	Linkage disequilibrium analysis of chromosome 12q14â€“15 in multiple sclerosis: delineation of a 118-kb interval around interferon-Î³ (IFNG) that is involved in male versus female differential susceptibility. Genes and Immunity, 2002, 3, 470-476.	2.2	40
99	Protein disulfide isomerase-mediated cell-free assembly of recombinant interleukin-12 p40 homodimers. FEBS Journal, 2000, 267, 6679-6683.	0.2	15
100	Polymorphism analysis suggests that the gelatinase B gene is not a susceptibility factor for multiple sclerosis. Journal of Neuroimmunology, 2000, 105, 58-63.	1.1	46
101	PECAM1, MPO and PRKAR1A at chromosome 17q21-q24 and susceptibility for multiple sclerosis in Sweden and Sardinia. Journal of Neuroimmunology, 2000, 108, 153-159.	1.1	28
102	Interferon gamma gene in rheumatoid arthritis. Lancet, The, 2000, 356, 2191.	6.3	8
103	A Dinucleotide Repeat Polymorphism Located in the IFN-Î±/Î² Gene Cluster at Chromosome 9p22 Is Not Associated with Multiple Sclerosis in Sardinia. Experimental and Clinical Immunogenetics, 1999, 16, 26-29.	1.4	6
104	Analysis of an IFN- gamma gene (IFNG) Polymorphism in Multiple Sclerosis in Europe: Effect of Population Structure on Association with Disease. Journal of Interferon and Cytokine Research, 1999, 19, 1037-1046.	0.5	41
105	Microsatellite polymorphisms in the gene promoter of monocyte chemotactic protein-3 and analysis of the association between monocyte chemotactic protein-3 alleles and multiple sclerosis development. Journal of Neuroimmunology, 1999, 95, 195-201.	1.1	24
106	GroEL/ES chaperonins protect interferon-gamma against physicochemical stress. Study of tertiary structure formation by alpha-casein quenching and ELISA. FEBS Journal, 1998, 251, 181-188.	0.2	9
107	Interferon-? gene polymorphism-associated risk for multiple sclerosis in sardinia. Annals of Neurology, 1998, 44, 841-842.	2.8	34
108	Interferon-Î³ is a target for binding and folding by both Escherichia coli chaperone model systems GroEL/GroES and DnaK/DnaJ/GrpE. Biochimie, 1998, 80, 729-737.	1.3	3

#	Article	IF	Citations
109	Recombinant Porcine IFN-Î³ Potentiates the Secondary IgG and IgA Responses to an Inactivated Suid Herpesvirus-1 Vaccine and Reduces Postchallenge Weight Loss and Fever in Pigs. Journal of Interferon and Cytokine Research, 1998, 18, 739-744.	0.5	18
110	Tumor necrosis factor Î± and its receptors in relapsing-remitting multiple sclerosis. Journal of the Neurological Sciences, 1997, 152, 51-61.	0.3	49
111	STRUCTURAL IMMUNO-ANALYSIS OF HUMAN AND PORCINE INTERFERON GAMMA: IDENTIFICATION OF SHARED ANTIGENIC DOMAIN. Cytokine, 1997, 9, 550-555.	1.4	11
112	Occurrence and clinical relevance of an interleukin-4 gene polymorphism in patients with multiple sclerosis. Journal of Neuroimmunology, 1997, 76, 189-192.	1.1	91
113	Improved conditions for the analysis of large variable number of tandemly repeated (VNTR) unit polymorphisms. Electrophoresis, 1996, 17, 678-680.	1.3	2
114	Two distinct interleukin-1? genes in the pig genome. Immunogenetics, 1994, 40, 82-82.	1.2	3
115	Refolding and single-step purification of porcine interferon-gamma from Escherichia coli inclusion bodies. Conditions for reconstitution of dimeric IFN-gamma. FEBS Journal, 1993, 215, 481-486.	0.2	30
116	Gene sequence, cDNA construction, expression in Escherichia coli and genetically approached purification of porcine interleukin-1beta. FEBS Journal, 1993, 217, 45-52.	0.2	17
117	Engineering by pcr-based exon amplification of the genomic porcine interferon-gamma DNA for expression in Escherichia coli. Biochemical and Biophysical Research Communications, 1991, 180, 1408-1415.	1.0	22
118	Nanopartikulen lipido konposizioak rHDLen kolesterol kanpora-fluxuaren efizientzian eragina du. , 0, , .		0